Emmaus Life Sciences, Inc., a Torrance, CA-based biotherapeutics company dedicated to the discovery, development and commercialization of treatments and therapies for debilitating rare diseases, raised approximately $7.5m in funding.
The company intends to use the funds for research and development, including the completion of its Phase 3 clinical trial for the treatment of sickle cell disease, commercialization costs, and for working capital and general corporate purposes.
Led by Yutaka Niihara, MD, MPH, CEO, President and Director, Emmaus is dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases.
FinSMEs
16/09/2013